In November of 2005, lawyers for Pfizer walked into a Chinese courtroom to fight for a word the company itself had never once used in an advertisement, a product label, or a single piece of official marketing. The word was 伟哥 (wei ge), and by then it was probably the single most recognizable drug name in the country. Pfizer lost. Then they appealed, and lost again. The reason why is one of the cleanest examples I know of language outrunning the company that supposedly owns it.
When Viagra launched in the United States in 1998, Pfizer needed an official Chinese name for its eventual entry into the world's largest pharmaceutical market. They settled on 万艾可 (wan ai ke), a phonetic transliteration that means, roughly, nothing at all. That's not a criticism of the translators, plenty of Western pharmaceutical names get this treatment, a name chosen for sound rather than meaning, safe, inoffensive, forgettable.
And forgettable is exactly what happened to it. 万艾可 (wan ai ke) never caught on in everyday speech. Almost nobody in China walks into a pharmacy and asks for it by that name.
Instead, ordinary people did what ordinary people do with any new, slightly embarrassing, slightly exciting product: they gave it their own name. 伟哥 (wei ge) started circulating almost immediately, translating loosely to "Mighty Brother" or "Powerful Big Brother." It's cheeky. It's a little proud of itself. It sounds like something a friend would say to you with a wink, not something printed on a pharmaceutical insert. Within a couple of years, 伟哥 (wei ge) wasn't slang anymore, it was simply the name. Doctors used it. Newspapers used it. It outpaced Pfizer's own official name so completely that most Chinese consumers likely had no idea 万艾可 (wan ai ke) was the "real" one.
Here's where the story turns from a marketing footnote into a genuine legal drama. In 1998, the same year Viagra launched in the US, a company called Guangzhou Welman Pharmaceutical filed to register 伟哥 (wei ge) as a trademark, for their own, entirely unrelated erectile dysfunction product. Under China's first-to-file trademark system, it doesn't matter who used a name first in the real world, it matters who filed the paperwork first. Welman's registration was approved in 2002.
By the time Pfizer realized what had happened, and tried to register 伟哥 (wei ge) for themselves, they were refused. The mark was already taken, and taken legally.
So Pfizer sued. Their argument was a real one, grounded in actual Chinese trademark law: if a mark becomes so strongly associated with a specific product in the public mind that it functions as a trademark, courts can sometimes protect it even without formal registration. Pfizer argued that 伟哥 (wei ge) had become exactly that, an unregistered but legally recognizable trademark belonging to them, through sheer weight of public use.
It's a genuinely clever legal theory. It's also where Pfizer's own paper trail worked against them. In court, Pfizer's own attorney confirmed, on the record, that the company's official commodity name for the drug was 万艾可 (wan ai ke). Pfizer admitted they had never used 伟哥 (wei ge) themselves, not in packaging, not in advertising, not anywhere official. The Beijing court, and later the Supreme People's Court on appeal, drew the obvious conclusion: you cannot retroactively claim ownership of a piece of language you never actually used, no matter how useful it turns out to be after the fact.
What makes this case even messier is that Pfizer was fighting on two fronts in China at once, and they weren't the same fight. Separately from the 伟哥 (wei ge) trademark dispute, twelve domestic Chinese drug companies jointly petitioned China's State Intellectual Property Office to invalidate Pfizer's actual patent on the drug's active ingredient, sildenafil. In July 2004, the Patent Review Bureau agreed and revoked the patent entirely, on the grounds that Pfizer's original application hadn't adequately documented the compound's specific therapeutic effect. For a moment, it looked like generic versions could flood the market legally. Pfizer fought back, and in 2006 the Beijing courts reversed the invalidation and restored the patent. Combine that with the separate trademark loss over 伟哥 (wei ge), and you get a company that spent close to a decade fighting on nearly every legal front available in China, over the same drug, at the same time.
What makes this case worth studying isn't the outcome, it's the mechanism. Pfizer didn't lose because a competitor tricked them or stole something. They lost because the Chinese-speaking public did what language communities do constantly and instinctively: they compressed an awkward, imported, meaningless phonetic string into something short, funny, and genuinely useful, entirely without corporate involvement. That's not vandalism of a brand. That's just how living language behaves when it meets a gap that needs filling.
The tragedy, from Pfizer's side, is that the nickname the public invented was objectively better than the one their marketing team paid for. 伟哥 (wei ge) is punchy, memorable, and slightly funny in exactly the way a name for this particular product should be. 万艾可 (wan ai ke) is none of those things. If Pfizer had noticed early enough, adopted the nickname as their own official use, put it on packaging, built ad campaigns around it, they likely could have owned it outright. Instead they let the market run ahead of them for years, and by the time they turned around to claim it, someone else already held the paperwork.
I bring this case up constantly with clients thinking about entering the Chinese market, because it cuts against the instinct most companies have. The instinct is: pick a safe, neutral, official name, and protect it. But safe and neutral is exactly what gets ignored. Chinese speakers are remarkably fast and creative at generating their own names for foreign products, whether you like it or not, and if you're not paying attention to what they're actually calling your product in the wild, someone else might file the paperwork before you do.
Pfizer did eventually win a separate trademark fight over the pill's distinctive shape, so it's not as though the company walked away from China empty-handed. But 伟哥 (wei ge), the name virtually every person in China actually uses when they talk about the little blue pill, that one, Pfizer never got back.